| Ytd | 10.62% | |
| 1y | -35.57% |
| Open | 1.16 | Prev Close | 1.18 | Low | 1.15 | High | 1.29 | Mkt Cap | 172.85M |
| Vol | 1.22M | Avg Vol | 1.04M | EPS | -1.20 | P/E | N/A | Forward P/E | -0.68 |
| Beta | 1.04 | Short Ratio | 8.58 | Inst. Own | 88.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-06 | 50-d Avg | 1.79 | 200-d Avg | 1.84 | 1yr Est | 7.67 |
ALXO News
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for con
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for con
BlackRock Inc. bought a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the unde
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onc
5AM Venture Management LLC acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ:
Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their se
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.11) per share which beat the an
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinica
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onco
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology co
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Suc
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onco
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to t
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highligh
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.15) per share which beat the an
- Data from Phase 1b/2 trial of evorpaceptzanidatamab presented at ESMO Breast Cancer 2026 showed al
The Phase 1b/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zani
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-drive
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 -SOUTH SAN FRAN
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRA
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Onc
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) saw a significant growth in short intere
Wells Fargo analyst Derek Archila initiates coverage on ALX Oncology Holdings (NASDAQ:ALXO) with
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:A
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.37) per share which missed the
Piper Sandler analyst Allison Bratzel maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Overwe
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology co
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology co
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session follow
It’s a red Tuesday for the U.S. stock market, with all major indices on Wall Street plummeting by ov
On Monday, 76 companies set new 52-week lows.